Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00771329 · ClinicalTrials.gov registry record · Phase 1
BIIB023 (Anti-TWEAK) in Subjects With Rheumatoid Arthritis
A Phase 1 study, sponsored by Biogen.
- Completed
- Registry status
- Phase 1
- Development phase
- 53
- Enrollment target
NCT00771329 is a Phase 1 study that has completed, run by Biogen. The registered enrollment target is 53 participants.
The verdict
NCT00771329, a Phase 1 study, has completed, sponsored by Biogen.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 53 participants
- Enrollment target
Study Summary
Phase I study designed to determine the safety and tolerability of a single dose of BIIB023 administered intravenously versus placebo to subjects with RA.
Interventions
- DRUG BIIB023
- OTHER Placebo (sterile normal saline)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 53 participants |
| Start Date | 2008-10 |
| Est. Completion | 2011-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00771329
The ClinicalTrials.gov registry entry for NCT00771329 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 53 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Biogen, which has 334 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which BIIB023 is the first listed.
NCT00771329 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00771329 about?
NCT00771329 is a clinical study titled "BIIB023 (Anti-TWEAK) in Subjects With Rheumatoid Arthritis". Phase I study designed to determine the safety and tolerability of a single dose of BIIB023 administered intravenously versus placebo to subjects with RA.
What is the current status of trial NCT00771329?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 53 participants. The study started on 2008-10. Estimated completion is 2011-04.
What interventions are being tested in trial NCT00771329?
The interventions under investigation include: BIIB023 (DRUG), Placebo (sterile normal saline) (OTHER).
Who is sponsoring clinical trial NCT00771329?
This trial is sponsored by Biogen, which has 334 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.